共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
Evidence on effectiveness of intensity‐modulated radiotherapy versus 2‐dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta‐analysis and a systematic review of the literature 下载免费PDF全文
Jayson Co MD Michael Benedict Mejia MD Janine Margarita Dizon PhD 《Head & neck》2016,38(Z1):E2130-E2142
4.
5.
6.
7.
18F‐Fluoromisonidazole positron emission tomography/CT‐guided volumetric‐modulated arc therapy‐based dose escalation for hypoxic subvolume in nasopharyngeal carcinomas: A feasibility study 下载免费PDF全文
Jianjian Qiu MS Bo Lv BS Meina Fu BS Xianglian Wang MS Xiangpeng Zheng MD Weihai Zhuo PhD 《Head & neck》2017,39(12):2519-2527
8.
Salvage endoscopic nasopharyngectomy and intensity‐modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma 下载免费PDF全文
Man‐Quan Deng MD Rou Jiang MD Ling Guo MD Qing Liu MD Hai‐Qiang Mai MD PhD Ming‐Huang Hong MD Ming‐Yuan Chen MD PhD 《Head & neck》2015,37(8):1108-1115
9.
Nabil F. Saba MD Joseph K. Salama MD Jonathan J. Beitler MD MBA Paul M. Busse MD PhD Jay S. Cooper MD Christopher U. Jones MD Shlomo Koyfman MD Harry Quon MD MS John A. Ridge MD PhD Farzan Siddiqui MD PhD Francis Worden MD Min Yao MD PhD Sue S. Yom MD PhD Expert Panel on Radiation Oncology–Head Neck Cancer 《Head & neck》2016,38(7):979-986
10.
11.
12.
Serglycin expression: An independent marker of distant metastases in nasopharyngeal carcinoma 下载免费PDF全文
Claramae Shulyn Chia MD Whee Sze Ong MAS Xin Jian Li PhD Yoke‐Lim Soong MD Fui Teen Chong BSc Hiang‐Khoon Tan MD PhD Khee‐Chee Soo MD Chao‐Nan Qian MD PhD Bin‐Tean Teh MD PhD N. Gopalakrishna Iyer MD PhD 《Head & neck》2016,38(1):21-28
13.
Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity 下载免费PDF全文
Jianhua Xu MD Xia He MD PhD Kong Cheng MD Wenjie Guo MD Xiuhua Bian MD Xuesong Jiang MD Lanfang Zhang MD Shengfu Huang MD 《Head & neck》2014,36(10):1474-1480
14.
Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience 下载免费PDF全文
Irene Karam MD FRCPC Shao Hui Huang MSc MRT MD Andrea McNiven PhD Jie Su MSc Wei Xu PhD John Waldron MD FRCPC Andrew J. Bayley MD FRCPC John Kim MD FRCPC John Cho MD FRCPC Jolie Ringash MD FRCPC Andrew Hope MD FRCPC Eric Chen MD FRCPC Biu Chan MSc David Goldstein MD FRCPC Brian O'Sullivan MD FRCPC Meredith E. Giuliani MD FRCPC 《Head & neck》2016,38(Z1):E1102-E1109
15.
16.
Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas 下载免费PDF全文
Wen Jiang MD PhD Paul D. Chamberlain BS Adam S. Garden MD Betty Y. S. Kim MD PhD Dominic Ma BS Emily J. Lo MD Diana Bell MD G. Brandon Gunn MD Clifton D. Fuller MD PhD David I. Rosenthal MD Beth M. Beadle MD PhD Steven J. Frank MD William H. Morrison MD Adel K. El‐Naggar MD Bonnie S. Glisson MD Erich M. Sturgis MD PhD Jack Phan MD PhD 《Head & neck》2016,38(Z1):E1459-E1466
17.
Koom WS Kim TH Shin KH Pyo HR Kim JY Kim DY Yoon M Park SY Lee DH Ryu JS Jung YS Lee SH Cho KH 《Head & neck》2008,30(2):159-169
BACKGROUND: Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy. METHODS: Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group). RESULTS: With a median follow-up of 26 months (range, 17-45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96% and 93%, 87%, and 88%, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67%) and 14 (59%) patients, respectively. Severe acute mucositis (100% vs 47%) and pharyngitis (100% vs 34%) were more frequently observed in the FP group than the DDP group (p < .01). CONCLUSIONS: Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution. 相似文献
18.
19.